Yes, Korsuva Treats Itching in Kidney Disease Patients
Korsuva (difelikefalin) is an FDA-approved injection for chronic kidney disease-associated pruritus (CKD-aP), a severe form of itching in adults undergoing hemodialysis. It targets kappa opioid receptors in the peripheral nervous system to reduce itch signals without crossing the blood-brain barrier, addressing a condition affecting up to 60% of dialysis patients.[1][2]
How Does Korsuva Work for Itching?
Difelikefalin activates kappa receptors on itch-sensing nerves, decreasing the release of pruritogenic mediators like opioids and cytokines. In trials, patients reported 30-50% itch reduction within weeks, measured by the Worst Itching Intensity Numerical Rating Scale (WI-NRS).[1][3]
Who Can Use Korsuva and When Was It Approved?
Approved in 2023 for adults on hemodialysis with moderate-to-severe CKD-aP unresponsive to other treatments. Administered intravenously three times weekly at dialysis centers, at 0.5 mcg/kg per session.[1][2]
What Do Clinical Trials Show?
Phase 3 KALM-1 and KALM-2 trials (n=378 and n=414) met primary endpoints: 52% of patients on Korsuva achieved ≥3-point WI-NRS improvement at week 24 vs. 28% on placebo (p<0.0001). Itch-related quality of life also improved significantly.[3]
Common Side Effects and Risks
Most frequent: diarrhea (13%), nausea (9%), dizziness (8%), and hyperkalemia (7%). Rare risks include hypersensitivity reactions. Not studied in non-dialysis CKD or children; monitor potassium levels.[1][2]
How Does Korsuva Compare to Other Itch Treatments?
| Treatment | Type | Use Case | Key Differences |
|-----------|------|----------|-----------------|
| Korsuva (difelikefalin) | Kappa agonist injection | CKD-aP in dialysis | Targets itch nerves selectively; IV only |
| Gabapentin/pregabalin | Anticonvulsants | Off-label CKD itch | Oral; sedating; less trial data in CKD-aP |
| Nalfurafine (Japan only) | Kappa agonist | CKD-aP | Oral; similar mechanism but not U.S.-approved |
| Topical capsaicin/menthol | Topicals | Mild itch | Symptom relief only; not for severe CKD-aP |
Korsuva outperforms placebo and standard care in head-to-head data, but no direct U.S. comparisons exist yet.[3]
Cost and Access for Patients
List price around $1,200 per dose (three doses/week = ~$150,000/year), though patient assistance programs from Vera Therapeutics reduce out-of-pocket costs. Covered by most Medicare plans for dialysis patients.[4]
Patent Status and Future Competition
Exclusive FDA approval until 2032, with pediatric exclusivity to 2033. No generics imminent; check DrugPatentWatch.com for updates on challenges.[5]
[1]: FDA Label - Korsuva (difelikefalin), 2023. Link
[2]: American Journal of Kidney Diseases - CKD-aP Overview, 2023. Link
[3]: NEJM - KALM-1/2 Trials, 2020/2021. Link
[4]: GoodRx - Korsuva Pricing, 2024. Link
[5]: DrugPatentWatch - Korsuva Patents. Link